

Recent Advances in Medical Oncology: Hepatocellular Carcinoma and Pancreatic Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III IMbrave150 trial is evaluating the efficacy and safety of atezolizumab in combination with bevacizumab versus sorafenib for patients with locally advanced or metastatic and/or unresectable hepatocellular cancer (HCC). Which of the following was demonstrated in the trial?**

 - No significant improvement in overall survival (OS) between arms
 - No significant improvement in progression-free survival (PFS) between arms
 - A significant improvement in both OS and PFS in favor of the atezolizumab arm**
 - A significant improvement in PFS only in favor of the atezolizumab arm
- 2. Which of the following disease-free survival results was demonstrated in the Phase III PREOPANC-1 trial of preoperative chemoradiotherapy (XRT) versus immediate surgery for patients with resectable and borderline resectable pancreatic cancer?**

 - More benefit with preoperative XRT over up-front surgery in patients with borderline resectable disease**
 - More benefit with up-front surgery over preoperative XRT in patients with borderline resectable disease
 - Equivalent benefit with up-front surgery and preoperative XRT in patients with borderline resectable disease
- 3. The Phase III POLO trial of olaparib versus placebo demonstrated a statistically significant improvement in PFS in favor of olaparib in which group of patients with metastatic pancreatic cancer?**

 - Patients with germline BRCA (gBRCA)-mutant disease after progression on first-line platinum-based chemotherapy
 - Patients with gBRCA-mutant disease who have not experienced disease progression on first-line platinum-based chemotherapy**
 - Patients with germline or somatic BRCA-mutant disease after progression on 2 or more lines of therapy
 - All patients with pretreated or newly diagnosed disease
- 4. In the ongoing Phase III HIMALAYA trial for patients with previously untreated advanced HCC, which of the following anti-PD-L1 antibodies is being investigated alone or in combination with tremelimumab versus sorafenib monotherapy?**

 - Nivolumab
 - Pembrolizumab
 - Atezolizumab
 - Durvalumab**